The diagnosis of hypersensitivity pneumonitis is difficult and often relies on histopathology. Our objective was to identify diagnostic criteria and to develop a clinical prediction rule for this disease.
INTRODUCTION
Hypersensitivity pneumonitis (HP) is a pulmonary disease with symptoms of dyspnea and cough resulting from the inhalation of an antigen to which the patient has been previously sensitized.
Acute and subacute HP represent the most active forms of the disease which may become chronic while remaining progressive. HP may also evolve to end-stage lung [1] . The diagnosis of HP has most often relied on an array of nonspecific clinical symptoms and signs developed in an appropriate setting [2] , with the demonstration of interstitial markings on chest radiographs, serum precipitating antibodies against offending antigens, a lymphocytic alveolitis on bronchoalveolar lavage (BAL), and/or a granulomatous reaction on lung biopsies.
When considered separately, none of these findings has proved useful in the diagnosis of HP.
It is accepted that 20% of chest radiographs are normal in the acute cases [3] . Many reports and reviews have challenged the diagnostic value of serum precipitins for case finding [4, 5] . BAL can provide supportive elements in the diagnosis of the disease. A normal lymphocyte BAL count rules out all but residual disease [6] , but an alveolar lymphocytosis is not specific of HP [7, 8] .
Transbronchial biopsies are of limited usefulness, even when granulomas are found [9] . Also, HP gives a typical but nonspecific pattern on high-resolution computed tomograms (HRCT) [10] .
Several groups have recommended diagnostic criteria for HP [11] [12] [13] , without their diagnostic accuracy being tested. Consequently, we conducted a prospective multi-center cohort study of patients presenting with a suspected diagnosis of acute, subacute or chronic HP. The objective was to develop a clinical prediction rule for the diagnosis of active HP (that is a clinical tool that quantifies the contribution that various components of the history, physical examination and basic laboratory results makes toward the diagnosis in an individual patient [14] ). Such a rule aims at helping clinicians to arrive at a more accurate estimate of probability of HP and decide whether further investigation is needed to either rule in or rule out HP. Some of the results of this study have been previously reported in the form of an abstract [15] .
METHODS

Patients
The HP Study involved seven clinical sites from as many countries (Appendix). Consecutive patients aged 18 presenting with a pulmonary syndrome for which HP was considered in the differential diagnosis were included in the study. This cohort thus comprised patients with and without HP in a proportion that was unspecified a priori. We excluded patients with suspected stage 1 sarcoidosis, those with a previous diagnosis of HP, and those referred for therapeutic evaluation of a known interstitial disease.
Diagnostic criteria under study
A review of the literature and consultations with content experts guided the development of a set of potential diagnostic criteria. These criteria included data usually collected during the initial investigation of patients with suspected HP (clinical history, physical examination, chest radiography markings pattern, pulmonary function testings, arterial blood gases, complete blood count, serum precipitating antibodies). Other clinical characteristics unlikely to be found in HP (such as pleural effusion or serum antinuclear antibodies) were also considered, given their potential for making the diagnosis of HP less likely.
Attending clinicians systematically recorded the relevant data in every patient before obtaining the final diagnosis. The symptoms and physical signs were recorded as present or absent on a standardized form during the initial clinical interview. The patients performed spirometry according to the American Thoracic Society requirements [16] , lung volumes measurement by plethysmography [17] , and carbon monoxide diffusion capacity measurement by the single-breath method [18] . The predicted values currently used within each laboratory were accepted. Arterial blood gases were 35 measured while breathing at room air. Partial pressure in oxygen was adjusted for altitude and reported as if it was obtained at sea level [19] . The investigators tested for serum precipitating antibodies in all patients using either the ELISA or the electrosyneresis methods [20] on a panel of antigens most likely to be encountered in their respective environment. The presence of antinuclear antibodies was tested by indirect immunofluorescent antibody staining of fixed cells [21] . We reported precipitating antibodies and antinuclear antibodies as being either positive or negative according to center-specific pre-defined threshold values. Finally, the chest X-ray available at the time of the initial consultation was assessed.
Gold standard
The investigators had to classify each patient as HP or non-HP. In the absence of a unique gold standard defining the presence or absence of HP, the final diagnosis relied on findings of BAL, HRCT and, if needed, other diagnostic procedures. BAL lymphocytosis ( 30% for non-and ex-smokers, and 20% for current smokers [22] ) and bilateral ground-glass or poorly defined centrilobular nodular opacities on HRCT [10] were required for the diagnosis of HP to be accepted without resorting to additional diagnostic procedures. When the association of HRCT and BAL did not allow the investigators to arrive with confidence at a final diagnosis of HP or non-HP, the decision regarding additional procedures (including for instance BAL fluid cytology or culture, transbronchial or endobronchial biopsy, or mediastinoscopy) was not protocol-based but left to the investigators, according to clinical circumstances and their usual practice. Patients underwent surgical lung biopsy when the HRCT, the BAL and other diagnostic procedures failed to yield a diagnosis. Pathological criteria of HP included chronic inflammatory infiltrates along small airways, diffuse interstitial infiltrates of chronic inflammatory cells, and scattered, small nonnecrotizing granuloma [23] . In the case a patient was classified as non-HP, a specific diagnosis was not mandatory, provided that HP was definitely excluded on the basis of BAL. Patients with inactive, late emphysematous or fibrotic sequelae of HP were classified in the control group. 
Statistical analysis
Derivation of the prediction rule:
In this analysis, we sought to reduce the list of potential diagnostic criteria to those that would recognize a high proportion of patients with HP and exclude a high proportion of patients with other diseases [24] . We first compared the clinical characteristics of the patients in the HP and non-HP groups using 2-tailed Fischer's exact or unpaired t-tests for dichotomous and continuous variables respectively. From this analysis, we incorporated the variables found significant at the 0.05 level in a stepwise logistic regression model. Odds ratios (OR) and 95% confidence intervals (CI) for the multivariate predictors were identified. We then constructed a receiver operating characteristic (ROC) curve (that is a plot of the true-positive vs. false-positive rates of HP at various thresholds of probability) using the predicted probabilities of HP from the logistic regression analysis as diagnostic tests for HP. Also, we computed the area under the ROC curve that indicates the probability that a random pair of HP and non-HP patients will be correctly classified as to their disease state [25] .
Validation: We prospectively validated the rule using a separate cohort of patients that met the same inclusion criteria as those included in the development phase of the study. During the phase of validation, the investigators were kept blind to the criteria identified during the derivation phase and were asked to collect the same data. In this analysis, the model developed in the derivation phase of the study was evaluated by comparing the areas under the ROC curve [25] . The hypothesis that the observed proportion of patients with HP was different from the predicted proportion in both the derivation and the validation cohort was tested using the goodness-of-fit statistic described by Lemeshow and Hosmer [26] . Finally, we constructed calibration curves that are plots of the observed probability of HP compared with the predicted probability of HP ordered by the increasing probability of the disease [27] .
In secondary analyses, in order to verify whether the rule can be applied in different settings, we cross-validated it by comparing, within each clinical site, the classification of each patient with their actual status. Also, in order to investigate the potential bias introduced by the use of information overlapping the criteria under study to define the presence or absence of HP, we constructed ROC curves using the subsets of patients who were submitted to surgical lung biopsy and those who were not.
Probability of HP:
The clinical prediction model yielded an equation expressing the probability of HP as a function of the statistically significant variables. From this equation, we constructed a table of probability for combinations of predictors.
RESULTS
Patients
Between February 1998 and September 2001, 728 patients were enrolled. Of those, 67 (9%) were excluded from the analysis by the adjudication committee for the following reasons: unavailable or uninterpretable BAL (n = 49) or HRCT (n = 9); inconsistent final diagnosis that could not be ascertained (n = 7); stage 1 sarcoidosis (n = 2). Thus, 661 patients (56% women; mean age: 55 years; standard deviation [SD]: 14) contributed to the analysis. The data from the first 400 patients (116 HP, 284 non-HP) were used to develop the prediction rule whereas those of the next 261 patients (83 HP; 178 non-HP) were used to validate it. The distribution of the final diagnoses is summarized in Table 1 
Derivation of the prediction rule
From the 18 variables that reached the level of statistical significance in the univariate analyses comparing the HP and non-HP groups (Table 2) , we excluded pO 2 since the absolute difference fell within the precision range of the test [29] . The logistic regression model identified 6 significant predictors of HP: (1) exposure to a known offending antigen; (2) positive precipitating antibodies to the offending antigen; (3) recurrent episodes of symptoms; (4) inspiratory crackles on physical examination; (5) symptoms occurring 4-8 hours after exposure; (6) weight loss ( Table 3 ). The area under the ROC curve (Figure 2 ) was 0.93 (CI: 0.90 -0.95). We determined that the threshold producing the most appropriate trade-off between sensitivity and specificity was a probability of HP of 45%. At this point of the ROC curve, the sensitivity of the rule was 86% (95% CI: 0.79 -0.92) and its specificity, 86% (95% CI: 0.81 -0.90). 
Probability of HP
The probability of HP computed for each of the 64 ( 2 6 ) combinations generated by the 6 significant predictors of HP is presented in Table 4 .
DISCUSSION
Interstitial lung diseases often pose diagnostic challenges, even to expert clinicians. Recent studies emphasized that additional investigations (including surgical biopsy) are indicated in patients with interstitial diseases in whom the diagnosis remains unclear following initial assessment [30, 31] . The results of the HP Study indicated that a simple clinical prediction rule may guide clinical practice by providing estimates of the probability of acute, subacute or chronic progressive HP from non-invasive testing. The predictors of HP we identified do not apply to chronic and inactive forms of the disease. The best diagnostic strategy will then depend on the probability of HP. For instance, in a farmer presenting with recurrent episodes of respiratory symptoms, inspiratory crackles and testing positive for the corresponding precipitating antibodies, the probability of HP would be 81% (Table 4) .
Another patient presenting with progressive dyspnea and inspiratory crackles as the unique criteria of HP would have a probability of HP of less than 1%. Further investigation would be mandated in the former. The typical findings of an alveolar lymphocytosis and/or bilateral ground-glass opacities on HRCT in the former patient would secure the diagnosis of HP, without resorting to surgical lung biopsy. However, HP would be confidently ruled out in the latter, and the investigation oriented elsewhere. We submit that a probability 90% or 10% should be sufficient in most cases to respectively rule in or rule out HP, especially in areas of high or low prevalence of HP respectively.
However, the « test threshold » (that is the probability below which a clinician would dismiss the diagnosis and order no further test) and the « treatment threshold » (that is the probability above which a clinician could consider the diagnosis confirmed and would stop testing) are likely to differ according to the clinical implications of the diagnosis [32, 33] . A clinician and his/her patient will be more likely to accept the diagnosis of bird fancier's disease when the offending antigen is a pet, even if the probability of HP is 75%. In such a case, antigen avoidance would be appropriate. Further investigation would be required only if the clinical course is unusual. On the other hand, a clinician and his/her patient will want to secure the diagnosis of farmer's lung even if the probability of HP is around 90%, given that more than 50% will quit farming within 6 years of a diagnosis of farmer's lung [34] .
Some of our findings deserve further attention. First, the enrollment of patients without interstitial disease stemmed from the inclusion criteria of the study: all patients presenting with a pulmonary syndrome for which active HP was considered were eligible. A typical example was the inclusion of patients (often farmers) who presented with recurrent episodes of dyspnea in whom the investigation ruled out HP and demonstrated asthma. Similarly, in four patients who presented with symptoms suggestive of HP, we could not demonstrate any lung disease. Second, the identification of a potential offending antigen is crucial for the clinical diagnosis of HP. Inquiry about occupational and home environmental exposures will most often uncover the cause of the disease. In rare instances (1.5% of our cohort), the diagnosis of HP was made without any identifiable offending antigen. In these cases, the diagnosis was supported by the careful exclusion of other causes of BAL lymphocytosis and typical findings of HP on lung biopsy. Third, although smoking is often thought of as having a protective effect against the development of HP [35] , non-smoking was not identified as an independent predictor of HP.
An important strength of the HP study was its adherence to methodological standards for both the derivation and the validation of the rule [14, 36] . The patients were chosen in an unbiased fashion and represented a wide spectrum of diseases from a variety of institutions, hence increasing generalizability. We included all perceived important predictors, and those of significance were present in a large proportion of the study population. The predictors and outcomes were clearly defined. In the absence of a unique gold standard defining HP, every effort was made to properly classify each patient as either HP or non-HP independently of the criteria under study. The final diagnosis relied on the combination of typical findings on BAL and HRCT and the exclusion of competing diagnoses. Surgical lung biopsy was available in 35% of the patients. An adjudication committee reviewed every case for consistency. We submitted the difficult cases to further investigation, including clinical reassessment providing follow-up information and a blind and independent review of the HRCT and biopsy material when available. The accuracy of the rule being less in the patients who were submitted to surgical lung biopsy than in those who were not does not necessarily indicate bias due to circularity. This may result from the fact that only the most difficult cases were submitted to surgical lung biopsy. Finally, considering an estimated annual incidence of interstitial lung disease of about 30 per 100,000 [37] , the sample size was large and determined a priori. The derived rule made clinical sense since it matched the expected typical findings in HP.
Potential applications of prediction rules include periodic surveillance in high-risk workers or case finding in outbreaks of HP. Several rules have been developed for such purposes [38] [39] [40] . Little information is available regarding their accuracy. Whether the rule we developed can be used for case-finding of HP remains uncertain. Because « exposure to a known offending antigen » is the strongest predictor of HP in our cohort of patients presenting with a variety of interstitial lung diseases (Table 3) , our rule may not retain its discriminative properties when used in a homogeneous population of workers all exposed to a common antigen.
Much confusion still surrounds the classification of HP. Its clinical presentations have classically been defined as acute, subacute and chronic [12] . The distinction between acute and subacute HP is often difficult as both likely represent different manifestations of a single disease that may be related more to the pattern of antigen exposure than to the offending antigen itself. This statement is supported by our finding of considerable overlap in the clinical manifestations of patients with farmer's lung (usually considered as the prototype of acute HP) and those with pigeon breeder's or bird fancier's diseases (the prototypes of subacute and chronic HP, respectively -data not shown).
Also, chronic HP may still be active and progressive. Others have suggested a classification that takes into account the progression of the disease (acute intermittent, acute progressive, chronic progressive, chronic nonprogressive) that can only be assessed retrospectively [1, 41] . For practical purposes, we suggest to consider HP patients as having either active or residual disease, the latter representing late emphysematous or fibrotic sequelae of the disease in which the typical alveolar lymphocytosis of active HP has disappeared.
The potential implications of such a simple rule are numerous. These simple criteria may Patients may have been submitted to more than one additional procedure.
Figure 2
Receiver operating characteristic (ROC) curve for the prediction rule. The probability of HP derived from the model can be considered as a diagnostic test, and the trade-off between sensitivity and specificity at various thresholds of the probability of HP is given by the ROC curve. Dotted line: derivation cohort; shaded area: validation cohort. • exposure to antigens 97% 33% < 0.001
• dyspnea 98% 86% < 0.001
• cough 91% 75% < 0.001
• chills 34% 14% < 0.001
• tightness of chest 35% 20% 0.002
• weight loss 42% 25% < 0.001
• body aches 24% 14% 0.018
• wheezing 31% 11% < 0.001
• chest (pleuritic) pain 10% 5% 0.040
• symptoms 4-8 hours after exposure 27% 2% < 0.001
• recurrent episodes of symptoms 44% 12% < 0.001
• smoking status: current smoker 6% 20% < 0.001
Physical signs
• fever 19% 7% 0.001
• inspiratory crackles 87% 72% 0.002
• wheezing 16% 10% 0.06
• cyanosis 32% 21% 0.030
• clubbing 21% 27% 0.21
• supraclavicular or cervical adenopathies 3% 4% 0.76 
